{"entity":{"id":"ma-fei","kind":"person","name":"Fei Ma","aka":[],"tldr":"A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.","summary":"Fei Ma is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She has led Chinese trials of pyrotinib and of HER2-directed antibody-drug conjugates, and studies circulating tumour DNA and resistance in HER2-positive breast cancer. Her publications include the phase 1 study and biomarker analysis of pyrotinib, a randomised phase 2 comparison of pyrotinib or lapatinib with capecitabine in pretreated HER2-positive metastatic breast cancer, and the PHILA phase 3 trial of pyrotinib added to trastuzumab and docetaxel as first-line treatment. Her interests are HER2, antibody-drug conjugates and liquid biopsy.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20F%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20pyrotinib"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["her2"],"drugs":["pyrotinib"],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Breast cancer","HER2","Antibody-drug conjugates","Circulating tumour DNA"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20F%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20pyrotinib"}],"papers":[{"title":"Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.00108"},{"title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","journal":"BMJ","year":2023,"doi":"10.1136/bmj-2023-076065"},{"title":"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.69.6179"}]},"route":"/people/ma-fei/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"}],"institution":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/"}]}}